Literature DB >> 2987430

Metrizamide myelography in patients with small cell carcinoma of the lung suspected of meningeal carcinomatosis.

A G Pedersen, O B Paulson, C Gyldensted.   

Abstract

Twenty patients suspected of meningeal carcinomatosis (MC) secondary to small cell carcinoma of the lung were evaluated by myelography and by cytologic examination of cerebrospinal fluid (CSF). In 4 patients both investigations demonstrated MC. Four had positive cytology but a negative myelogram. Five patients had a positive myelogram but negative cytology. Thus 13 of the 20 patients had MC diagnosed by one or both of these investigations. Two additional patients suspected of MC were studied; both had positive myelography, but cytologic examination of CSF was not performed in either case. Six patients underwent autopsy with microscopic examination of the spinal cord; in all cases post-mortem findings supported myelographic findings. In conclusion, myelography is useful in the evaluation of patients suspected of MC secondary to small carcinoma of the lung and complements the diagnostic role of CSF examination.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987430     DOI: 10.1007/bf00165176

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  8 in total

1.  CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival.

Authors:  J L Nugent; P A Bunn; M J Matthews; D C Ihde; M H Cohen; A Gazdar; J D Minna
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

2.  Meningeal carcinomatosis from small cell carcinoma of the lung. Consequence of improved survival.

Authors:  J Aisner; S C Aisner; S Ostrow; S Govindan; K Mummert; P Wiernik
Journal:  Acta Cytol       Date:  1979 Jul-Aug       Impact factor: 2.319

3.  Spinal meningeal carcinomatosis in small-cell carcinoma of the lung.

Authors:  H D Brereton; J F O'Donnell; C H Kent; M Matthews; N R Dunnick; R E Johnson
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

4.  Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology.

Authors:  J P Glass; M Melamed; N L Chernik; J B Posner
Journal:  Neurology       Date:  1979-10       Impact factor: 9.910

5.  Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings.

Authors:  F R Hirsch; O B Paulson; H H Hansen; J Vraa-Jensen
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

6.  Diagnostic cytology of cerebrospinal fluid by the cytocentrifuge method.

Authors:  H S Choi; P J Anderson
Journal:  Am J Clin Pathol       Date:  1979-12       Impact factor: 2.493

7.  Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience.

Authors:  S T Rosen; J Aisner; R W Makuch; M J Matthews; D C Ihde; M Whitacre; E J Glatstein; P H Wiernik; A S Lichter; P A Bunn
Journal:  Medicine (Baltimore)       Date:  1982-01       Impact factor: 1.889

8.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

  8 in total
  4 in total

Review 1.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

2.  Diagnosis and treatment of patients with meningeal carcinomatosis.

Authors:  H Nakagawa; A Murasawa; S Kubo; S Nakajima; Y Nakajima; S Izumoto; T Hayakawa
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

Review 3.  Leptomeningeal metastases: a review of evaluation and treatment.

Authors:  M C Chamberlain
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

4.  Comparative spine imaging in leptomeningeal metastases.

Authors:  M C Chamberlain
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.